Physician profile
Bruce M Ackerman
NPI 1154327633
$3,373.67
in general payments reported to CMS, 2019-2025
33 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 78% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $271 · 2021: $55.79 · 2022: $168 · 2023: $466 · 2024: $614 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.33 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $403.37 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Sunovion Pharmaceuticals INC. | $325.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $270.48 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Grifols USA, LLC | $194.73 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $173.44 | 2019-2025 | Dupixent |
| Genzyme Corporation | $168.35 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $162.10 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Amgen INC. | $151.77 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $146.99 | 2020-2025 | Glassia |
| Gilead Sciences, INC. | $139.90 | 2023-2024 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.64 | 2022-2025 | Ofev, Stiolto Respimat |
| Intuitive Surgical, INC. | $130.58 | 2025 | |
| Pfizer INC. | $111.13 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $102.89 | 2019-2023 | Xarelto |
| Philips North America LLC | $97.06 | 2019-2025 | Vest Therapy Und |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.31 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Mylan Specialty L.P. | $83.02 | 2020-2024 | Yupelri |
| Alexion Pharmaceuticals, INC. | $62.78 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $53.96 | 2022-2024 | Acthar |
| Viatris Specialty LLC | $49.27 | 2025 | Yupelri |
| Allergan, INC. | $47.24 | 2019 | |
| Insmed, INC. | $44.39 | 2025 | Brinsupri, Arikayce |
| Abbvie INC. | $44.01 | 2021-2022 | |
| Genentech USA, INC. | $37.33 | 2019-2020 | |
| Verona Pharma, INC. | $22.51 | 2025 | Ohtuvayre |
| Inogen, INC. | $22.00 | 2025 | |
| Lilly USA, LLC | $19.60 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $18.53 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $16.70 | 2024 | |
| Paratek Pharmaceuticals, INC. | $14.19 | 2020 | |
| Shire North American Group INC | $12.86 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $12.18 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.